Articles tagged "Immunosuppression"

2016 American Transplant Congress
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus: A Cost-Effectiveness Analyses.
H. Tedesco-Silva, C. Felipe, A. Brigido, M. Cristelli, M. Paula, A. Bessa, P. Ruppel, J. Medina-Pestana.
Nephrology Division, Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
A cost-effectiveness analysis was performed using data from a prospective single center trial where de novo kidney transplant recipients received a single 3 mg/kg dose…
2016 American Transplant Congress
Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome.
M. Tseng,¹ S. Ge,¹ R. Roberts,² C. Kuo,² J. Choi,¹ N. Nissen,¹ M. Chu,¹ I. Kim,¹ B. Shin,¹ M. Toyoda,¹ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pediatrics & Immunology, UCLA, Los Angeles, CA.
Introduction: Monoclonal antibodies that disrupt CD40/CD40 ligand (CD40L) interactions are likely to have utility in human transplantation. However, the extent of the immunosuppressive effects of…
2016 American Transplant Congress
Association of Smoking Habits with Comorbidity 15 Years After Liver Transplantation.
S. Pischke,³ M. Lege,¹ L. Fischer,² U. Herden,² A. Lohse,³ B. Nashan,² M. Sterneck.¹
¹University Transplant Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; ²Department of Hepatobiliary Surgery and Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany; ³Department of Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany.
Background and aimsThe survival rate of liver transplant (OLT) recipients has strongly improved over the last years. Here we investigate the association between long term…
2016 American Transplant Congress
First Bilateral Hand Transplant in a Child: Short-Term Medical Outcomes and Challenges.
S. Amaral,¹ M. Levine,² B. Chang,² S. Lopez,¹ C. McAndrew,² S. Kessler,¹ A. Shaked,² L. Levin.²
¹Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA; ²Surgery, University of Pennsylvania, Philadelphia, PA.
Background: In July 2015, our center successfully performed the first bilateral hand transplant in a pediatric patient in the United States. The recipient was an…
2016 American Transplant Congress
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.
H. Hirsch,¹ J. De Fijter,¹ M. van der Giet,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ H. Holdaas,¹ J. Cruzado.¹
¹ELEVATE Study Group, Basel, Switzerland; ²Novartis, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover.
BackgroundCytomegalovirus (CMV) and BK polyomavirus (BKPyV) infections are independent risk factors for acute rejection and graft loss. Early conversion from calcineurin inhibitors (CNIs) to everolimus…
2016 American Transplant Congress
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.
P. de Simone,¹ P. Carrai,¹ A. Precisi,² L. Coletti,¹ D. Ghinolfi,¹ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospitals, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy.
Background: No trial has so far investigated everolimus (EVR)-incorporating immunosuppressive regimens versus combined use of tacrolimus (TAC) and mycophenolate mofetil (MMF) in liver transplantation (LT).Materials…
2016 American Transplant Congress
Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation.
P. Espie, J. Munz, T. Flandre, B. Haraldsson, P. Ulrich, J. Rush.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
Background. CD40-CD154 pathway blockade significantly prolongs renal allograft survival in non-human primates (NHPs), and trials of the novel blocking, non-depleting anti-CD40 monoclonal antibody (mAb) CFZ533…
2016 American Transplant Congress
Impact of Immunosuppressants on Inducing Regulatory T Cells in Human Allo-Immune Responses.
Y. Tanaka, H. Ohdan.
Transplant Surgery, Hiroshima University, Hiroshima, Japan.
A better understanding of cytokine signaling pathways involving transcription factors of the STAT family in T cells responding to allostimulation will improve interpretation of immune-regulatory…
2016 American Transplant Congress
Kidney Transplant Patient Preferences and Trade-Offs for Outcomes After Transplantation.
M. Howell,^1,2 G. Wong,^1,2,3 J. Rose,⁴ A. Tong,^1,2 J. Craig,^1,2 K. Howard.²
¹Centre for Kidney Research, The Childrens Hospital at Westmead, Westmead, NSW, Australia; ²School of Public Health, University of Sydney, Sydney, NSW, Australia; ³Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia; ⁴Institute of Choice, University of South Australia, North Sydney, NSW, Australia.
Aim: To evaluate preferences and trade-offs patients may accept to avoid adverse outcomes of long-term immunosuppression. Background: Patient preferences in clinical decisions are increasingly relevant,…
2016 American Transplant Congress
Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 7 Years Follow-Up.
Y. Watarai, M. Okada, K. Futamura, T. Nagai, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi.
Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; Kidney Transplant Surgery, Aichi Medical University, Nagoya, Aichi, Japan.
Purpose: Long-term efficacy and safety of everolimus (EVR) based immunosuppression for de novo kidney transplant recipient who were involved in A1202 study from our institute…